Background 28 Host immune responses at the site of Mycobacterium tuberculosis (Mtb) infection serve to contain the 29 pathogen, but also mediate the pathogenesis of tuberculosis (TB) and onward transmission of 30 infection. Based on the premise that active TB disease is predominantly a manifestation of 31 immunopathology, we tested the hypothesis that immune responses at the site of host-pathogen 32 interactions would reveal enrichment of immunopathologic responses in patients with active TB that 33 were absent in individuals with equivalent immune memory for Mtb but without disease. 34
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77
Immune responses at the site of TST in active and cured TB 78 The TST has been most extensively used to identify patients with T cell memory for mycobacterial 79 antigens, but the clinical response does not differentiate infected individuals with and without active 80 disease (1) . We sought to test the hypothesis that molecular profiling of the TST may identify elements 81 of the recall response which are specifically associated with disease. We undertook 48-hour TSTs in 82 patients with microbiologically-confirmed TB disease within the first month of treatment ('active TB') 83 to identify disease associated responses, and compared these to TST responses in patients within one 84
year of curative TB treatment ('cured TB') to identify non-disease associated recall responses (table  85 TST of people with active TB compared to that of cured TB, but expression of IFN, type I IFN or 141 TNF-inducible gene modules was not significantly different between the two groups ( fig 4A) . We 142 extended our approach to evaluating the functional bioactivity of other specific cytokines using 143 transcriptional modules for IL-10-and IL-4/IL-13-inducible gene expression, described in a previous 144 report (5). Neither of these were significantly different in the TST of people with active and cured TB 145 ( fig S3A) . The IL-4/IL-13 bioactivity module was used as a measure of Th2 responses normally 146 associated with allergy and immune responses to helminths. Another member of the IL-17 family, IL-147 17E contributes to Th2 responses (11). We found no enrichment of IL-17E expression in the TST of 148 people with active TB consistent with IL-4/IL-13 bioactivity and distinct from IL-17A/F bioactivity (fig  149   S3B ). 150
Focusing on mechanisms that may contribute to pathogenesis, enrichment of MMP-1 expression in 151 the TST of patients with active TB (fig 2) can also be attributed to increased IL-17A/F bioactivity, 152 through induction of MMP expression by stromal cells (20) . Neutrophils can also contribute to the 153 immunopathology of TB (14-16, 21, 22), and a key function of IL-17A/F is to promote neutrophil 154 recruitment via induction of neutrophil chemokines (12). Therefore, we tested the hypothesis that the 155 TST in active TB will also reveal increased neutrophil recruitment, compared to that of patients with 156 cured TB. We compared the expression of two independently derived transcriptional modules that 157 have been extensively validated to reflect neutrophil frequency in tissues including the TST (23, 24). 158
We found significantly higher expression of the neutrophil modules in people with active TB compared 159 to cured TB ( fig 4B) . These differences were mirrored by gene expression levels of IL-17A-inducible 160 CXCL1, CXCL8 and S100A9 that drive neutrophil recruitment to sites of inflammation (11, 15) ( fig 4C) . 161
In contrast, accumulation of monocytes and T cells assessed by their respective gene expression 162 modules (23), and the expression of the monocyte chemoattractant, CCL2, did not differ in the TST of 163 people with active and cured TB ( fig 4B&C) . 164
Increased frequency of Th17 cells in active TB TST responses 165 IL-17A/F are predominantly produced by Th17 cells and neutrophils (11). Immunohistochemistry 166 revealed that in the TST of people with active TB, IL-17F, originated predominantly from mononuclear 167 cells, rather than from polymorphonuclear cells ( fig 5A) . Therefore, we tested the hypothesis that 168
Th17 cells were enriched in the TST of people with active TB compared to that of cured TB. We derived 169 transcriptional modules specific for differentially polarised CD4+ Th subsets from a published dataset 170 In order to investigate the mechanism for increased Th17 responses in the TST of patients with active 178 TB, we tested the hypothesis that active TB was also associated with increased circulating Th17 cells. 179
We assessed the expression of the Th subset modules in the transcriptome of PPD-stimulated PBMC 180 from an independent cohort of individuals with active TB disease and latent TB infection (28). In 181 contrast to that observed in the TST, patients with active TB revealed enrichment for the 182 Th1-associated gene expression module in PBMC but showed no difference in the Th17-associated 183 module ( fig 5C) . As a result, we explored the alternative hypothesis that the inflammatory 184 environment generated at the site of TST promotes the Th17 differentiation observed in patients with 185 active TB. We investigated the expression of cytokines implicated in Th17 differentiation, IL-1, IL-6, 186 IL-23 and TGF (11). The expression of each of these was significantly correlated with enrichment for 187 Th17 cells in the TST of active TB. In contrast there was no correlation with IL-12 and IL-4 expression 188 that drive Th1 and Th2 cell differentiation respectively ( fig 5D) . These data support a model in which 189 the local tissue microenvironment may promote Th17 differentiation within tissues in active TB. 190 IL-17 activity is not a feature of latent TB and is not confounded by demographic background, vaccinations, IL-17A/F responses drive neutrophil-mediated pathology (14-16, 21). We infer from 243 these data that IL-17A/F responses may play a dichotomous role in TB by contributing to protection in 244 early infection, but to the pathology of disease if early infection is not controlled and multibacillary 245 bacterial replication and chronic immune activation ensues. Additional support for this model is 246 evident in IL-27R deficient mice, which exhibit exaggerated Th17 responses because they lack IL-27 247 inhibition of RORT (37). These mice show enhanced clearance of Mtb, but also increased 248 immunopathology dependent on IL-17A. Interestingly, a human candidate gene study identified host 249 genetic variation associated with increased secretion of IL-17A to be correlated with both protection 250 from incident TB but also more severe TB disease (38). Taken together, we hypothesise that 251 exaggerated IL-17A/F recall responses are the consequence of chronic multibacillary infection, but in 252 turn mediate increased pathology in established disease. Of the other IL-17 family members that signal 253 via alternative receptors, much less is known about the functional role of IL-17B, IL-17C and IL-17D 254 (11). These cytokine responses were not specifically tested in the present study. IL-17E, known to 255 promote Th2 responses (11), was not differentially enriched in active TB. Equally, we found no 256 evidence of elevated IL-10 responses in active TB, indicating an uncoupling of IL-17A/F activity from 257 regulatory responses, driving immunopathology rather than the control of Mtb replication (39). 258
Another cytokine, IL-22, does have functional overlap with IL-17A/F (17), but did not discriminate 259 between people with and without disease in our study. 260
Our data support the hypothesis that exaggerated IL-17A/F responses arise from Th17 cells, but they 261 do not unequivocally exclude other cellular sources. Our immunohistochemical analysis did not show 262 any clear evidence for IL-17F production by polymorphonuclear cells in the TST, but we were not able 263 to test whether other lymphocyte populations, such as  T cells, made a significant contribution (35, 264 40, 41) . Future studies will require single cell resolution to definitively confirm the source of 265 The study comprised recruitment of several different populations. The discovery 'Active TB' group that 295 formed the basis of most of the analyses in figs 1-5 was the HIV seronegative patients from the same 296 cohort described in our previous publication (5), who were recruited from TB clinics in London, UK and 297 Cape Town, South Africa, and were all within one month of commencing antibiotic therapy. The 298 comparator 'Cured TB' group was an independent cohort recruited from TB clinics in London, UK and 299 Lima, Peru who fulfilled the inclusion/exclusion criteria (table S1). All 'Cured TB' patients were less 300 than 2 years after completion of curative anti-TB antibiotic therapy for drug sensitive disease. In 301 addition, a separate validation cohort of patients with active TB was recruited from TB clinics in 302 London ( fig 6) . These patients were also within one month of commencing antibiotic therapy. This 303 population was compared to individuals with latent TB recruited from TB clinics in London and Lima, 304 who fulfilled inclusion/exclusion criteria (table S1). All study participants were HIV seronegative and 305 for those with active or cured TB, the presence of Mtb infection was confirmed by routine culture or 306 molecular based methods according to local clinic protocols. The demographic, clinical and laboratory 307 data for each study group is summarised in table S2. for module sensitivity and specificity as determined in our previous publication (23). These were 375 previously generated and validated the specificity of macrophage response modules to IL-10 or IL4/IL-378 13 stimulation (5), and these are also utilised in this manuscript. Mann-Whitney test. 583 
